Transferrin Receptor Expression by Retinal Pigment Epithelial Cells in Proliferative Vitreoretinopathy

Baudouin, Christophe; Brignole, F.; Gastaud, P

doi:10.1001/archopht.1991.01080090017007

Cited by 9 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transfection of iris and ciliary body with the Crx homeobox gene expressed in photoreceptor cells results in synthesis of rhodopsin in the non-photoreceptor structures of the eye [16]. The expression of the lacZ gene under the influence of the rhodopsin promoter in multiple structures of the eye is consistent with prior work showing the TfR is widely expressed in multiple structures of the eye, including the iris, ciliary body, corneal endothelium, the conjunctival epithelium [17], as well as the RPE, the retinal endothelium, and cells of the inner retina [14]. The TfR is also expressed in cells of the choroid [14], although the TfR expression on endothelium of choroidal capillaries is less than the expression of the TfR on the endothelium of retinal capillaries [18].…”

Section: Discussionsupporting

confidence: 85%

Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

Zhu

Zhang

et al. 2004

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

Zhu

Zhang

et al. 2004

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…The transgene was also expressed in the iris and ciliary body following administration of either the SV40-LacZ (Figure 9D) or the GFAP-LacZ (261). Gene expression in the extra-retinal structures of the eye such as the iris or ciliary body is consistent with expression of the TfR in these structures (264,265). Expression of the GFAP-LacZ in the iris and ciliary body is also consistent with the known GFAP expression in these regions of the eye (266,267).…”

Section: Blindnesssupporting

confidence: 69%

Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

Pardridge

2020

Front. Med. Technol.

View full text Add to dashboard Cite

Non-viral gene therapy of the brain is enabled by the development of plasmid DNA brain delivery technology, which requires the engineering and manufacturing of nanomedicines that cross the blood-brain barrier (BBB). The development of such nanomedicines is a multi-faceted problem that requires progress at multiple levels. First, the type of nanocontainer, e.g., nanoparticle or liposome, which encapsulates the plasmid DNA, must be developed. Second, the type of molecular Trojan horse, e.g., peptide or receptor-specific monoclonal antibody (MAb), must be selected for incorporation on the surface of the nanomedicine, as this Trojan horse engages specific receptors expressed on the BBB, and the brain cell membrane, to trigger transport of the nanomedicine from blood into brain cells beyond the BBB. Third, the plasmid DNA must be engineered without bacterial elements, such as antibiotic resistance genes, to enable administration to humans; the plasmid DNA must also be engineered with tissue-specific gene promoters upstream of the therapeutic gene, to insure gene expression in the target organ with minimal off-target expression. Fourth, upstream manufacturing of the nanomedicine must be developed and scalable so as to meet market demand for the target disease, e.g., annual long-term treatment of 1,000 patients with an orphan disease, short term treatment of 10,000 patients with malignant glioma, or 100,000 patients with new onset Parkinson's disease. Fifth, downstream manufacturing problems, such as nanomedicine lyophilization, must be solved to ensure the nanomedicine has a commercially viable shelf-life for treatment of CNS disease in humans.

show abstract

“…It is possible that iron is normally transported by the nonpigmented epithelium into the aqueous, where it would bind transferrin and supply the iron needs of the nonvascularized ocular tissues: the lens epithelium and the cornea. In support of this hypothesis, there is strong immunoreactivity to TfR antibodies in the human lens epithelium 35 and corneal endothelium. 36 The iron-overloaded DKO retinas had a decrease in levels of TfR.…”

Section: Discussionmentioning

confidence: 64%

Ceruloplasmin/Hephaestin Knockout Mice Model Morphologic and Molecular Features of AMD

Hadziahmetovic

Dentchev

Song

et al. 2008

Invest. Ophthalmol. Vis. Sci.

112

View full text Add to dashboard Cite

show abstract

Transferrin Receptor Expression by Retinal Pigment Epithelial Cells in Proliferative Vitreoretinopathy

Cited by 9 publications

References 5 publications

Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

Ceruloplasmin/Hephaestin Knockout Mice Model Morphologic and Molecular Features of AMD

Contact Info

Product

Resources

About